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FOREWORD
Phenylketonuria (phenylpyruvic oligophrenia) and branch- 
ed-chain ketonuria (maple syrup urine disease) are inborn 
errors of essential amino acid metabolism. Phenylketonuria 
was first observed by Falling in 193** and branched-chain 
ketonuria was described by Menkes, Hurst, and Craig in 195**. 
Both disorders share common features which suggest that they 
may have a common biochemical etiology while the genetic 
defects are dissimilar autosomal recessive traits. In each 
case, no prenatal damage has been detected, but following 
birth, the clinical symptoms become apparent. The major 
clinical features shared by phenylketonuria and branched- 
chain ketonuria are muscular hypertonicity, vomiting, con­
vulsive seizures, mental retardation, and premature death.
The symptoms of phenylketonuria are less severe than those of 
branched-chain ketonuria while the incidence of phenylketon­
uria is higher than that of branched-chain ketonuria. The 
occurence of phenylketonuria has been estimated to be one 
case in 25,000 births and that of branched-chain ketonuria to 
be one in 250,000 births. Both disorders are pan-ethnic, 
with the reported incidence higher in technologically advanc­
ed areas due to the increased ability to diagnose them. The 
incidence of phenylketonuria and branched-chain ketonuria, as 
well as other recessive genetic defects, is at least ten 
times higher in the region of Louisiana known as Acadiana.
This has been attributed to the geographic isolation of the 
Acadians from the early l600*s to the late 1800*s and the 
subsequent consanguinity of the marriages.
The onset of clinical manifestations in phenylketonuria 
is delayed for one to two months postpartum. By the end of 
the first year, the undiagnosed patient is transformed from 
an apparently normal baby into a quite retarded one. In 
addition to the features common to branched-chain ketonuria 
patients, phenylketonuria patients make no attempts to walk 
or talk. They are also hyperkinetic and microcephalic. 
Estimated intelligence quotients for untreated phenylketon- 
urics from ages 3 to 9 are 30 to *f0. Electroencephalograph 
abnormalities suggest deep midline brain damage. Three- 
quarters of phenylketonurics die by age 30 from infectious 
diseases (i.e., pneumonia, tuberculosis, and nephritis).
The appearance of symptoms in branched-chain ketonuria 
occurs during the first week following birth. The suckling 
response is lost and the urine acquires an odor character­
istic of maple syrup or burned sugar. The hypertonicity, 
vomiting and seizures common to phenylketonuria are evident 
along with apnea and lethargy. Death usually occurs in the 
first year and survival past the second year is rare. While 
many of the symptoms are similar to phenylketonuria, their 
onset is much more rapid and acute. Severe mental retarda­
tion is always manifest when the branched-chain ketonuria 
patient survives for a period sufficiently long enough
iv
to measure mental development.
Phenylalanine hydroxylase is a liver enzyme that is 
part of a dihydrobiopterine dependent hydroxylating system 
that is also considered to be responsible for the hydroxy- 
lation of tyrosine and tryptophan. In phenylketonuria, 
an inactive phenylalanine hydroxylase is produced by the 
defective gene and precludes the conversion of phenylalanine 
to tyrosine. As a result, the phenylalanine metabolites 
accumulate from the alternate routes of phenylalanine 
metabolism. Phenylalanine and its metabolites are elevated 
in the plasma along with several tryptophan metabolites.
Branched-chain ketonuria results from the defective 
catabolism of the branched-chain amino acids, leucine, iso­
leucine, and valine. They are transaminated normally to 
their correspnding a-ketoacids, but the oxidative decarboxy­
lation to the acyl-Coenzyme A derivatives is blocked. The 
branched-chain a-ketoacids, are normally metabolized in the 
liver and to a minor degree in the kidney. The decarboxy­
lation of the branched-chain a-ketoacids (BCKA) is catalyzed 
by a multienzyme dehydrogenase system similar to the multi­
enzyme complexes involved in pyruvate and a-ketoglutarate 
decarboxylation. It has not yet been resolved whether 
there are one or more BCKA dehydrogenase complexes affected 
in the diseased state. As result of the interrupted BCKA 
metabolism the branched-chain amino acids and their a-keto­
acids accumulate in abnormally high levels in the plasma
v
along with indoleacetic acid.
In both disorders! it is accepted that the elevated 
metabolite levels adversely affect normal biochemical 
systems. The major systems affected are energy metabolism, 
transport, and biosynthesis of proteins, lipids, neuro­
transmitters, and myelin. In general, the abnormally high 
a-ketoacid levels in phenylketonuria and branched-chain 
ketonuria are considered to elicit the similar clinical 
symptoms by affecting many of the same biochemical processes. 
This report will elaborate on the effects of the branched- 
chain ketonuria and phenylketonuria metabolites on a part­
icular aspect of the disruption of energy metabolism. The 
results will be discussed in relation to the proposed common 
etiology of the disorders found in phenylketonuria and 
branched-chain ketonuria.
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ABSTRACT
Branched-chain ketonuria (BCKU) and phenylketonuria 
(PKU) are inborn errors of amino acid metabolism resulting 
in mental retardation and premature death. BCKU is due to 
the genetic inability to sythesize a functional branched- 
chain a-ketoacid dehydrogenase to oxidatively decarboxylate 
the a-ketoacids of leucine, isoleucine, and valine trans­
aminations. The genetic defect in PKU is the synthesis of a 
mutant phenylalanine hydroxylase incapable of oxidizing 
phenylalanine to tyrosine. In both disorders the amino 
acids and their corresponding a-ketoacids accumulate in the 
serum to high levels (10 mM), The most offensive metabo­
lites are a-ketoisocaproate (KIC) in BCKU and phenylpyruvate 
(PPA) in PKU. The reduced postpartum myelination leading to 
retardation is thought to be due to the lack of necessary 
precursors and defective energy metabolism.
Demonstration of a pyruvate transport system and the 
subsequent reports that this system was inhibited by PPA 
and KIC were taken as the explanation of the depressed 
energy metabolism. PPA and KIC were soon shown not to be 
as effective pyruvate transport inhibitors as originally 
reported. Electron micrographs showing disruption of mito­
chondrial integrity in the presence of 0,1 mM PPA or KIC 
suggested that the disease metabolites exerted their effects




To test this possibility, a study of the effects of the 
BCKU and PKU a-ketoacids on the respiration parameters of 
the succinate oxidase system in mouse liver mitochondria was 
undertaken. This system was chosen since it is an integral 
membrane enzyme associated with the electron transport sys­
tem and disturbances in its membraneous environment could 
be detected through changes in its respiratory parameters. 
The oxidation of 7*5 mM succinate was monitored with a 
Clark oxygen electrode at 37° C and pH 7.^. The a-ketoacids 
were added to a final concentration of 7.5 mM, PPA reduced 
the State 3 oxidation rates 10-20$ while KIC had no effect. 
The State k rates were increased 10-30$ by KIC and 20-^7$ 
by PPA. The acceptor control ratios (ACR) were reduced 8- 
23$ by KIC and 23-^5$ toy PPA. The ADP/0 ratios were reduced 
6-10$ by KIC and 12-20$ by PPA. The reduction of the ACR 
was found to be concentration dependent. Reduction of the 
ACR by PPA was detected at levels below 1 mM, while the KIC 
effect was observed at 2.5 mM.
The increase in the State k oxidation rates and the 
decreases in the ACR's and the ADP/0 ratios indicate that 
PPA and KIC are partially uncoupling succinate oxidation 
from ADP phosphorylation. The decrease of State 3 oxi­
dation by PPA indicates that it is an electron transport 
inhibitor. These findings are supportive of the observation 
that PPA and KIC are perturbing mitochondrial structure.
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In doing so, these compounds reduce the efficiency of oxi­
dative phosphorylation and the result is a decrease of ATP 
available for biosynthesis in the rapidly developing new­
born afflicted with PKU or BCKU. This partial uncoupling of 
oxidative phosphorylation and the concomitant inhibition of 
other enzyme systems by PPA and KIC could produce a general 
depression of energy metabolism in the neonate that would 
impair the myelination process and result in permanent 
mental retardation.
It is apparent from these results and those from other 
laboratories that there is no single biochemical phenomenon 
responsible for the mental retardation and other symptoms 
of PKU and BCKU. It appears that these genetic disorders 
produce their similar devastating abnormalities through an 
accumulation of many small effects due to the reduction in 
the effiency in energy production and the inhibition of the 
biosynthesis of the necessary developmental metabolites.
INTRODUCTION
Branched-chain ketonuria (BCKU) (see Appendix 1 for 
abbreviations used) and phenylketonuria (PKU) are the result 
of inherited disorders in essential amino acid metabolism 
(1,2,3). In each case, the normal metabolism is blocked due 
to a genetically defective enzyme system. The oxidation of 
phenylalanine to tyrosine by phenylalanine hydroxylase is 
the specific metabolic disorder in PKU, The loss of this 
enzymatic reaction leads to the accumulation of phenyl­
alanine metabolites by the alternate pathways shown in 
Figure 1. Less than 50# of the excess phenylalanine is 
incorporated into protein, leaving the remainder to be con­
verted to phenyl ethyl amine (PEA), phenylpyruvic acid (PPA.), 
phenyllactic acid (PLA), o-hydroxyphenyllactic acid (HPLA), 
and phenylacetic acid (PAA). The aberrant biochemical event 
in BCKU is the oxidative decarboxylation of the a-keto ana­
logs of the branched-chain amino acids. As shown in Figure 
2, there is normal transamination of leucine, isoleucine, 
and valine to their branched-chain a-ketoacids (BCKA). The 
defective BCKA dehydrogenase(s) prevent the decarboxylation 
and the subsequent formation of the respective acyl-Coenzyme 
A derivatives. As in PKU, the BCKU metabolites, leucine, 
valine, isoleucine, alloisoleucine, a-ketoisocaproic 
acid (KIC), a-ketoisovaleric acid (KIV), and a-keto-P- 
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Figure 2. Branched-Chain Amino Acid Degradation Showing the Reactions Blocked in BCKU.
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levels in blood and urine.
A comparison of the PKU and BCKU metabolites with some 
intermediates of the citric acid cycle show that they share 
the a-ketoacid structure as seen in Figure 3* This similar­
ity in structure suggests that the disease metabolites 
possess the potential for acting as alternate substrates, 
substrate analogs, or even inhibitors of the energy related 
reactions involving pyruvate, a-ketoglutarate, and oxalo- 
acetate. The merit of this suggestion is demonstrated in 
Table 1 which is a compilation of the metabolic systems 
whose normal function is adversely affected by the metabo­
lites of BCKU and PKU. A large number of processes or 
enzymes listed are directly or indirectly involved in the 
production of energy. The majority of the remaining systems 
utilize the energy produced by the other reactions. It is 
immediately obvious that if the energy production machinery 
of the cell is depressed, the systems which utilize that 
energy will also be depressed. Of all the systems listed 
in Table 1, over half of them are affected by the PKU and 
BCKU metabolites. Those systems that are not listed as 
being affected by the metabolites of both disorders have 
generally not been tested for deleterious effects by the 
toxic compounds produced in each disease. Of the 23 systems 
listed in Table 1 that are affected by the metabolites of 
both diseases, about two thirds of them can be directly or 
indirectly related to cellular energy production. The 
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Figure 3» Structural Analogy of the PKU and BCKU Metabolites 
with Certain Energy Metabolites and a-Cyano-A-hydroxy- 
cinnamic Acid.
TABLE 1
Metabolic Systems Affected by Phenylketonuria and Branched-Chain Ketonuria Metabolites.*
Process or Enzyme Tissue Phenylketonuria Branched-Chain Ketonuris
Affected ^ or M  Svstenr^ Metabolite(s )## Ref. Metabolite (s Ref.
Acetoacetate Oxidation B PPA 58 KIC 58
Acetoacetyl-CoA Thiolase B Phe,PPA UrJ
Acetyl-CoA Carboxylase B PPA 24
Acetylcholinesterase B Leu 8
Acetylcholine Synthesis B Phe, PPA KIC,KMV,KIV 44
Amino Acid Transport B,H Phe,PPA 8,56,6o Leu,Val,Ile 8,56
Cell Growth Fb.Lb KIC,KMV,KIV,Leu 26,48
Citrate Synthase B PPA 24 KIC.KMV 29
DOPA Decarboxylase A PPA,PLA,PAA 5
Fatty Acid Synthetase B PPA 24 KIC,KMV,KIV 29,44
Gluconeogenesis K,L PPA 53,5k>
Glutamate Decarboxylase B PPA 7 KIC,KIV 7





3-Hydroxybutyrat e Dehydrogenase B
3-Hydroxybutyrate Oxidation B
3-Hydroxybutyrate Transport B
5-Hydroxytryptophan Decarboxylase K 
Insulin Release P





































Nucleic Acid Synthesis B
3-0xoacid CoA Transferase B
Oxygen Consumption B









PPA 36,37 KIC 36,37
Phe 2,3,4, KIC 1,3,
10,49 4,12,
49
PPA 16 KIC,KMV,KIV 44
PPA ,HPAA ,PLA 43
PPA, PAA 9 KIC,KIV 9
PPA 16




PPA 18,23 KIC,KIV,KMV 14,17,
19,25,
28,29,44
Phe 13,30, KIC,KMV,KIV 44
44


























Transaminati on B,L Leu,KIC,KIV 33
* These are systems in which effects have been observed. The absence of an enzyme or 
system from this compilation implies that there is no effect or it has not been examined.
** Where no metabolite is given, the effect was observed in the diseased state or an 
animal model.
The process or enzyme activity was diminished except in the case of insulin release 
which was increased.
# # Abbreviations:
A - adrenal 
B - brain 
B1 - blood 
E - erythrocyte 
Fb - fibroblast 
H - heart
HPAA- o-hydroxyphenylacetic acid 
H e  - isoleucine 
K - kidney
KIC - a-ketoisocaproic acid 
KIV - a-ketoisovaleric acid





PAA - phenylacetic acid
PEA - phenylethylamine
Phe - phenylalanine
PLA - phenyllactic acid
PPA - phenylpyruvic acid
Val - valine
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energy-requiring, biosynthetic transformations. Those 
biochemical systems that are not affected by the metabolites 
of both diseased conditions also may be classified as 
either biosynthetic or energy-generating. In general, the 
metabolites of PKU and BCKU depress energy metabolism and 
in so doing, reduce the normal functioning of developmental 
and biosynthetic pathways.
Most of the major clinical symptoms common to BCKU and 
PKU, hypertonicity, ketosis, seizures and coma, are revers­
ible through dietary therapy (1 ,2 ,3 ,8). The mental retard­
ation is not reversible and is thought to be due to the 
depressed myelination observed in the brains and nervous 
tissue of BCKU and PKU patients (4 ). Myelination is the 
process by which Schwann cells or oligodendrocytes form 
the spirally arranged "insulating" sheath around peripheral 
and central nervous tissue. The process occurs primarily 
during postpartum development. The major portion of the 
myelin sheath is composed of a proteolipid matrix formed 
from hydrophobic proteins and complex lipids. The defective 
myelination observed (1 ,2 ,3 ,4 ,1 0,1 2, 4 9) may be directly 
attributed to the reduced lipid synthesis (1 ,2 ,4 ,10,1 6,2 1, 
22,27,3 5 i4 4,4-9) and protein synthesis (8 ,1 6,4 4,52). An 
indirect contributing factor could also be the decreased 
energy metabolism as outlined in Table 1.
The suggestion that the irreversible neurological 
defects in PKU and BCKU were due to the inhibition of 
brain respiration during the developmental stages by the
11
elevated levels of PPA, KIC, KMV, and KIV was first develop­
ed by Tashian in 1961 (7)* Following Tashian*s suggestion, 
reports of disruption of energy metabolism by BCKU and PKU 
metabolites began to appear. Oxygen consumption in brain 
slices was lowered by 10 to 20# (9). Using manometric 
techniques, Gallagher showed that pyruvate oxidation in 
brain mitochondria was inhibited by PPA (11). A series 
of reports by Bowden and his colleagues demonstrated that 
PPA and KIC competitively inhibited the oxidative decarbox­
ylation of pyruvate and a-ketoglutarate decarboxylation in 
isotonic brain and liver homogenates (1^,17,18,19,21,28).
KIC and KIV were shown to inhibit pyruvate and a- keto- 
glutarate oxidation in brain mitochondria (15)• It was also 
reported that a-ketoglutarate dehydrogenase activity was 
inhibited in a non-competitive fashion by KIC in sonicated 
rat heart mitochondria (15)• Land and Clark reported that 
pyruvate dehydrogenase activity from thrice frozen and 
thawed rat brain mitochondria were not affected by PPA (23, 
75)• The apparent contradiction to previous evidence by 
Land and Clark (23) and Lysiak et al. (15) may be explained 
by the demonstration that repeated freezing and thawing in­
activates a-ketoglutarate dehydrogenase by degrading the 
phospholipids required for its activity (6l). Since 
a-ketoglutarate dehydrogenase and pyruvate dehydrogenase 
are similar multienzyme complexes(62) and sonication also 
decomposes phospholipids (62), either of these treatments 
could affect the enzymatic activities of these two similar
12
multienzyme complexes from the mitochondrial matrix. Other 
reports have also shown the a-ketoacids of both diseases 
inhibit a-ketoglutarate and pyruvate decarboxylation (25, 
29,34,44,47,63,6*0 • In those studies where the type of 
inhibition was determined, it was found to be competitive 
(29,34,47163164)■ From these studies it can be seen that 
the PKU and BCKU a-ketoacids are detrimental to two pivotal 
processes in oxidative energy metabolism.
The first indication that anaerobic energy metabolism 
was affected was Appel's report that leucine inhibited 
lactate dehydrogenase (8). There have been subsequent 
observations of the inhibition of lactate dehydrogenase 
by PPA (21,51)* Weber has reported that phenylalanine is 
a competitive inhibitor of pyruvate kinase and that PPA 
is an inhibitor of hexokinase (13)* Weber and his col­
leagues have also shown that the conversion of triose- 
phosphates to pyruvate is inhibited by PPA along with 6- 
phosphogluconate dehydrogenase being inhibited (16). A 
general reduction of glucose utilization in liver and brain 
induced by the BCKU and PKU metabolites is also shown (l6, 
30,44). It would appear that from these observations the 
normal operation of anaerobic oxidation is also impaired by 
the BCKU and PKU metabolites.
It is still unknown what the tissue concentrations of 
the PKU and BCKU metabolites are in an acute seizure. In 
the untreated, nonconvulsive patients the metabolic levels 
in plasma and urine are in the ranges of 0.1 to 10 mM (1,2,
3). The studies discussed above have generally employed 
metabolite levels within this range in their in vitro ex­
periments. The diverse tissue preparations used (perfu­
sions , slices, homogenates, whole mitochondria, frozen and 
thawed mitochondria, and sonicated mitochondria) in these 
studies do not lend themselves to immediate or uncomplicat­
ed interpretations of the situation in vivo. A prime 
example of this confusion can be seen when comparing rela­
tive tissue pyruvate levels in experimentally induced PKU 
in rats and relative plasma pyruvate levels in two PKU 
patients. In the experimentally induced PKU, the pyruvate 
levels in brain and liver were reduced 50% and 20% respec­
tively (30)- The plasma pyruvate levels in the PKU patients 
were twice that of the controls (42). The decreased pyr­
uvate levels in the PKU patients could be accounted for 
by the inhibition by PPA of pyruvate carboxylase (20,42,4*7), 
pyruvate decarboxylation (18,23), and lactate dehydrogenase 
(21,51)* The contradictory results of these reports are 
not readily reconciled and nor can the results of the stud­
ies employed explain the disparate pyruvate levels observed. 
It may be that in the experimental PKU the phenylalanine 
level may not have approached the threshold level neces­
sary to be transaminated to PPA, The plasma concentration 
of phenylalanine required for transamination to occur is 
0,5 mm (3). There were no plasma phenylalanine concentra­
tions given for the induced PKU study but the liver and 
brain levels were 3*33 and 0,051 ramol/g tissue, respective-
ly. These values may he roughly translated into 3.33 mM 
and 0.051 mM by assuming that one gram of tissue is approx­
imately equal to one milliliter of plasma. The assumption 
clearly places the brain phenylalanine level far below that 
required for transamination. The liver phenylalanine con­
centration, by this assumption, is far above that neces­
sary for transamination to PPA. The pyruvate levels in 
both tissues were reduced but the level in brain was 
depressed far greater than that in the liver. The phenyl­
alanine was injected one hour prior to the sacrifice of the 
rats and there may not have been sufficient time for trans­
amination to produce the amount of PPA required to inhibit 
the pyruvate utilizing enzyme in the liver to elevate the 
pyruvate level to that reported for the PKU patients. The 
plasma phenylalanine concentration in the PKU patients 
was ^ mM and was sufficiently high enough for transamina­
tion to PPA.
This suggests that in PKU the metabolic aberrations 
occur on two levels which are dependent on the plasma 
phenylalanine concentration. When the phenylalanine level 
is below 0.5 mM, key glycolytic enzymes may be inhibited 
and the developing brain is deprived of its energy from 
glucose. A dietary load of protein could send the plasma 
phenylalanine above 0.5 mM and begin its transamina­
tion to PPA. The PPA could then inhibit the primarily 
mitochondrial synthetic reactions and oxidative energy 
metabolism (see Table 1). A similar mechanism may be
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operating in BCKU also. The Michaelis constants (Km) of the 
substrates of the branched-chain amino acid transaminase 
isozyme I responsible for the majority of the branched-chain 
amino acid transamination are about 1 mM (65). The tissue 
concentration of the branched-chain amino acids is on the 
order of 0.1 mM (66). In order for appreciable transamina­
tion to occur, the level of branched-chain amino acids must 
be elevated at least ten-fold, as in BCKU. Elevated branch­
ed-chain amino acids at concentrations below the Km of the 
transaminase may be responsible for the chronic or irrevers­
ible biochemical abnormalities in BCKU while the branched- 
chain a-ketoacids that accumulate when branched-chain amino 
acid levels are elevated to concentrations in excess of the 
Km of the transaminase could spark the acute or reversible 
symptoms of BCKU,
The evidence that the metabolism of the branched-chain 
amino acids is controlled, at least in part, at the level of 
transamination is substantial (65). It is also evident that 
phenylalanine metabolism is regulated by its transamination 
(3). It is tempting to speculate, as above, that the chronic 
and acute (irreversible and reversible) symptoms observed in 
PKU and BCKU are the result of amino acid and a-ketoacid 
levels controlled by specific transaminases.
The continuing interest in the defective energy 
metabolism in BCKU and PKU and the seemingly contradictory 
evidence concerning the effects of the disease metabolites 
on pyruvate oxidation lead Land and Clark to suggest that
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there may he an impairment of mitochondrial pyruvate per­
meability (29). The existence of a specific mitochondrial 
pyruvate transporter had been proposed earlier by Papa et 
al. (67) but the proof of its existence was delayed due to 
the lack of a specific inhibitor of pyruvate transport. 
Using oc-cyano-4— hydroxycinnamate (CHC) (see Figure 3)1 
Halestrap and Denton demonstrated inhibition of pyruvate 
transport mitochondria and erythrocytes (68). Further 
evidence supporting the existence of a pyruvate transporter 
was soon forthcoming (38,39,4-0,69,70.72,7*0 . Data regard­
ing the kinetic and exchange properties of the pyruvate 
carrier suggest that it should be more generally called the 
monocarboxylate transporter as the system was shown to be 
responsible for the transmembrane relocation of p-hydroxy- 
butyrate (32*38,55,70), PPA (38), acetoacetate (55*70), 
lactate (39,70,73). KIC (38,4-0), and KIV (4-0).
Accompanying the elucidation of the function of the 
monocarboxylate translocase, were reports that the various 
BCKU and PKU metabolites inhibited mitochondrial pyruvate 
influx and efflux. Halestrap and his colleagues observed 
that PPA and KIC inhibited pyruvate transport in liver and 
brain mitochondria (31,38,71,73)* Other investigators have 
also demonstrated the inhibition of pyruvate exchange in 
mitochondria by MSUD and PKU metabolites (39*^0,4-5,4-6,55* 
69). Mitochondrial transport of p-hydroxybutyrate has also 
been shown to be inhibited by PPA and KIC (4-5)* These ob­
servations of inhibition of pyruvate and P-hydroxybutyrate
transport were interpreted as being the cause of the di­
minished oxidation of these substrates by PPA and KIC (11, 
15»29,31132»^5»50»69»71)• This interpretation was gener­
ally accepted in consideration of the apparently conflic­
ting data concerning the inhibition of the pyruvate 
dehydrogenase complex by PPA and KIC previously discussed.
STATEMENT OF PROBLEM
In order to examine the phenomenon of the inhibition 
of pyruvate transport and its relationship to the patho­
genesis of PKU and BCKU, the isolation and purification 
of the translocase complex was attempted. The isolation 
of a membrane-free monocarboxylate translocase would obviate 
the need for the involved pyruvate transport assay, A 
simple assay for pyruvate binding and the subsequent effects 
of the PKU and BCKU metabolites on the binding could be 
performed by equilibrium dialysis. Affinity chromatography 
was chosen as the method of isolation. The ligand attached 
to the agarose matrix was CHC, the pyruvate transport 
inhibitor (For preparation of the affinity gel, see Appendix 
2). Mouse liver mitochondria, disrupted by either 
digitonin or Triton X-100, were applied to the CHC column 
and nearly all of the protein was recovered in a single 
peak. Addition of high concentrations of pyruvate or CHC 
to the elution medium did not remove any additional protein 
from the column. This indicated that the translocase was 
either not bound to the column or had been denatured in 
some manner on the gel or prior to its application on the 
column. At that same time, it was reported that the bind­
ing of CHC to the translocase was highly transient and
could not be stabilized by ultraviolet light and oxidizing 
or reducing agents (?6). This indicated that the trans-
locase probably would not bind to the CHC affinity chroma­
tography column. Thus, this line of investigation was 
considered futile and was promptly abandoned.
While the BCKU and PKU metabolites were shown to be 
competitive inhibitors of pyruvate transport, it was also 
noted that they were also transported across the mitochon­
drial membranes (38»39»40,55). Once having gained entry 
into the mitochondrial matrix, these ketoacids may adverse­
ly affect the metabolic systems contained in that metabolic 
compartment. Using an improved technique, Paradies and 
Papa (40,55) demonstrated that PKU and BCKU metabolites 
were not as effective as inhibitors of pyruvate transport 
as originally reported by Halestrap {31,38). Straight- 
chain ketoacids (a-ketobutyrate, a-ketovalerate, a-keto- 
caproate and acetoacetate)-were more potent inhibitors 
of pyruvate transport than the branched-chain and aromatic 
a-ketoacids found in BCKU and PKU (40,55)- Consideration 
of the facts that the BCKU and PKU a-ketoacids are capable 
of entry into mitochondrial matrix and they are less potent 
inhibitors of pyruvate transport than originally surmised 
indicates that while inhibition of pyruvate transport 
is undoubtedly a contributing factor in the etiology 
of the abberrant metabolism observed in the diseased 
states, it may not totally account for all of the bio­
chemical deficiencies amassed in Table 1. The carbohydrate 
utilization studies of Gibson and Blass showed that the 
disease metabolites reduced the production of ^COg
20
from glucose or [2- ^ 0] pyruvate more than that
from El-^C] pyruvate (kk). They also reported that the
activity of the <x-ketoglutarate dehydrogenase complex was
inhibited to a greater extent than pyruvate dehydrogenase
complex. They interpreted these data as an indication
that the primary action of the a-ketoacids is on the Krebs
cycle at some point other than the pyruvate dehydrogenase
1^complex. The differential production of CO2 from the 
variously labelled pyruvates implied that the inhibition 
of pyruvate transport and pyruvate dehydrogenase complex 
were minor effects, as suggested by the work of Paradies 
and Papa mentioned above, Gibson and Blass further sur­
mised that there must be more than one reaction of the 
Krebs cycle affected in the diseased state since acetyl- 
Coenzyme A derived from either [2-^c]pyruvate or [u-^c] 
glucose must pass through the complete cycle at least 
once before being oxidized to .
Using electron microscopy, Bowden et al. have observed 
disruption of mitochondrial membrane integrity in the 
presence of O.lmM KIC and PPA (36,37)* To investigate 
the effects of this membrane disruption by PPA and KIC 
on a mitochondrial enzyme system and simultaneously examine 
the possiblility that more than one Krebs cycle reaction 
is affected in PKU and BCKU, a study of the effects the 
PKU and BCKU metabolites on the oxidation of succinate 
oxidase system was undertaken. The succinate oxidase
system (succinate*ubiquinone oxidoreductase) is known to be 
Complex II of the four electron transport complexes (78,79, 
80,81,82). The protein components of Complex II are suc­
cinate dehydrogenase (EC 1.3.99.l) and cytochrome ^
in a 1*1 ratio. The succinate oxidase system is bound to 
the inner surface (matrix side) of the inner mitochondrial 
membrane. Thus, succinate dehydrogenase is the only mem­
brane-bound Krebs cycle enzyme and as such is well suited 
to the proposed line of investigation. The polarographic 
measurement of succinate oxidation in whole mitochondria 
permits the determination of several respiratory parameters 
(83). The oxygen consumption rates in the various mito­
chondrial metabolic states as defined by Chance and 
Williams can be measured (84-). The five different meta­
bolic states are characterized in Table 2 in terms of the 
available respiratory substances and the respiratory rates 
in the presence of excess inorganic phosphate (Pi). The 
mitochondrial respiration rates of interest in this study 
are those of State 3 and State In State 3* the maximum 
oxygen consumption rate is obtained and the only limiting 
factor is the availability of the electron transport sys­
tem. Adenosine diphosphate (ADP) is the rate-limiting 
compound in State A respiration where the oxygen consump­
tion rate is considerably reduced in comparison to that of 
State 3* State 3 is a condition wherein active respiration 
is occurring and ADP is being phoBphorylated concomitantly 
with oxygen consumption by the electron transport chain.
TABLE 2
The Mitochondrial Respiratory State Characteristics According to Chance and Williams(8^).
State Oxygen ADP Substrate Respiration Rate-limiting
Level Level Level Rate Factor
1 greater than zero low low slow ADP
2 greater than zero high zero slow substrate
3 greater than zero high high fast respiratory chain
4 greater than zero low high slow ADP
5 zero high high zero oxygen
rvj
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State k is a "resting" state induced by the depletion or 
lack of the phosphate acceptor, ADP. This regulation of the 
respiratory rate by ADP has been called respiratory control 
but is now more correctly known as acceptor control since 
the respiratory rate is determined by the presence of the 
phosphate acceptor (8l). The degree or extent of acceptor 
control is given by the acceptor control ratio (ACR). The 
ACR is defined as the ratio of the State 3 respiratory 
rate to the State ^ respiratory rate immediately following 
that State 3 period(85). Whole mitochondria whose ADP 
phosphorylation is intimately associated with the electron 
transport involved in substrate oxidation are said to be 
tightly coupled. Tightly coupled mitochondria characteris­
tically exhibit high ACR's and high P/0 ratios (molecules 
of Pi per atom of oxygen consumed during ADP phosphoryla­
tion ) (81). A high ACR is a more rigorous demonstration 
of mitochondrial integrity than is the efficiency of oxi­
dative phosphorylation as measured by P/0 ratios. It 
has been shown that high P/0 ratios may be observed in 
mitochondria with low repiratory control (81,86). An 
estimate of the efficiency of oxidative phosphorylation 
can be determined from the ratio of ADP added to initiate 
State 3 respiration to the oxygen consumed during State 3» 
This quantity known as the ADP/O ratio is equivalent to 
the classical P/0 ratio (87).
The respiratory parameters discussed above will be 
determined for the succinate oxidase system from mouse liver
mitochondria in the presence and absence of the BCKU and 
PKU metabolites. Liver was the tissue of choice for this 
study as liver mitochondria are easier to prepare and liver 
cells contain more mitochondria than brain cells. (81,86). 
Also, considerable data on the effects of the PKU and BCKU 
a-keto-acids on brain respiration has been reported while 
very little information is available on their involvement 
in liver metabolism# It is known that liver ketone body 
levels and gluconeogenesis are disturbed by PKU and BCKU 
metabolites(16,*4-2,Ml,51) « An impairment in the sources 
of energy available from the liver for the developing and 
adult brain could be a partial explanation for the reduced 
myelination during the development and subsequent seizures 
observed in PKU and BCKU. The effects of the disease meta­
bolites on the structure and metabolism of liver mitochon­
dria as measured by the respiratory parameters of the 
succinate oxidase system may be useful in elucidation of 
the etiology of these similar inborn errors of metabolism.
EXPERIMENTAL PROCEDURES
A. Reagents
The chemicals employed in this work were of reagent 
quality or better and were used without further purification. 
The sucrose and potassium hydroxide (KOH) were products of 
Mallinckrodt chemical works. Matheson, Coleman, & Bell 
Manufacturing Chemists produced the succinic acid and 
L -(-)- tyrosine. The urea, sodium hydroxide (NaOH), and 
sodium chloride (NaCl) were products of Fisher Scientific 
Co. Merck & Co. produced the copper sulfate (CuS0/j.*6H20) .
The sodium potassium tartrate (NaKC^H^O^'^HgO), magnesium 
chloride (MgCl2*6H2), monobasic potassium phosphate (KHgPO^), 
and dibasic potassium phosphate (KgHPO^) were products of 
J. T. Baker Chemical Co. Tyrosinase (polyphenol oxidase; 
Grade III), 0 -NADH (yeast;Grade III), cytochrome c (equine 
heart; Grade III ), ADP (equine muscle; Grade I), BSA (Cohn 
Fraction V; 96-99$ albumin), Triton X-100, HEPES, EGTA, KIC, 
KMV, KIV, and PPA were obtained from Sigma Chemical Co. 
Aldrich Chemical Co. supplied the a-cyano-^-hydroxycinnamic 
acid (CHC). U. S. Industrial Chemicals Co. produced the 
absolute ethanol. All water used was charcoal filtered 
and deionized on a mixed-bed resin supplied by Continental 
Water Co. and then distilled in all-glass still.
B. Solutions
The preparation of all solutions is given in Appendix 3»
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The standardization of the ADP, NADH, and tyrosine solutions 
is given in Appendix
C . Isolation of Mouse Liver Mitochondria (MLM)
The mice used as a source of mitochondria were the C-^ 
strain obtained from Sprague-Dawley. They were maintained 
on a 12 hour light and dark cycle with free access to Purina 
Laboratory Chow and tap water. The isolation technique 
used is a modification of the preparations of Johnson and 
Lardy (86) and Chappell and Hansford (88). Adult mice of 
either sex were sacrificed by cervical dislocation, decapi­
tated, and exsanguinated. The livers were quickly removed 
and placed in ice-cold MLM isolation medium (see Appendix 3) 
after the removal of the gall bladders. From this point, 
all operations were performed on ice or at C using ice- 
cold solutions and implements. The livers were blotted, 
weighed, and scissored into small pieces in MLM isolation 
medium. The bloody solution was decanted, more MLM medium 
was added, and the liver pieces were minced a second time. 
After decanting the liquid, the minced liver was homogenized 
in 9 volumes (9 x liver weight) of MLM isolation medium with 
6 manual passes of an all-glass Dounce homogenizer (0.10- 
0.15 mm clearance). The homogenate was centrifuged in the 
SS-34 rotor of a Sorvall RC-2B centrifuge at 2000 revolutions 
per minute (rpm)(^80 x gravity) for 10 minutes. The super­
natant was carefully decanted and recentrifuged at 10,000 
rpm(12,000 x gravity) for 10 minutes. The supernatant was 
discarded along with the pink ’'fluffy layer” of microsomes
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on the top of the tan mitochrondrial pellet. The pellet
was resuspended with a glass stirring rod and the suspension
was diluted to one half of the original homogenate volume
with MLM isolation medium and then dispersed with a Potter-
Elvehjem homogenizer with a Teflon pestle (0.10-0.15 mm
clearance). The suspension was centrifuged at 10,000 rpm
for 10 minutes and the supernatant was discarded along with
the "fluffy layer" as before. The pellet was resuspended
in one quarter of the original homogenate volume with MLM
isolation medium and again dispersed with the Potter -
Elvehjem homogenizer. This second suspension was centrifuged
at 10,000 rpm for 10 minutes and the supernatant and "fluffy
layer" (if any) were discarded. The pellet was resuspended
and dispersed in a volume of MLM isolation medium equal to
the original weight of the livers. The dark brown "button"
adhering to the bottom of the centrifuge tube following each
high speed (10,000 rpm) centrifugation was not resuspended
with MLM since this results in mitochondria with lower
rates of oxygen consumption. This preparation takes about
l£ hours to complete and averages about 19 mg protein/ ml.
This procedure incorporates HEPES into the MLM isolation
medium. HEPES has been shown to be a superior buffer for
the isolation of mitochondria (89) and for the determination
of mitochondrial respiratory parameters (89,90). EGTA is
2+also included in the MUW isolation medium to chelate Ca
ions. EGTA is preferred to EDTA in that EGTA does not 
2+extract Mg ions from the mitochondrial membranes and
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making them leaky to K*- ions (88). Ca^+ ions should he ex­
cluded from the isolation and assay media as they uncouple 
oxidative phosphorylation and cause a loss in acceptor con­
trol (81,91).
D. Protein Determination
Mitochondrial protein was determined hy a modified 
biuret method (92) since the HEPES buffer interferes with 
the Lowry protein assay (93)* To four samples of 0.1 ml of 
the mouse liver mitochondrial preparation were added 0.1 ml 
of Triton - urea reagent and water to a total of 1.5 ml. 
Biuret reagent (1.5 ml) was added to three of these samples 
and 1.5 ml of 3$ sodium hydroxide was added to the fourth 
to provide a blank. Standard protein (BSA) and water blanks 
were run simultaneously in a like manner with the unknowns. 
All samples were incubated for JO minutes at 37° for full 
color development. The absorbance of each sample* standard, 
and blank were measured on a Beckman DB spectrophotometer 
at 5^0 nanometers. The biuret standard curve constructed 
for this work is given in Appendix 5•
E. Oxygen Determination
The oxygen content of the succinate oxidase assay 
medium was determined by two separate titration methods.
The first method employed the NADH titration (9^) of oxygen 
via the electron transport chain of saline-washed mitochon­
dria in the presence of cytochrome c (95)• Mouse liver 
mitochondria were prepared as described above and were 
resuspended in 10 ml cold water. This suspension was kept
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at C for 2 hours and then centifuged at 10,000 rpm for 
30 minutes. The pellet was resuspended in 10 ml of cold 
0.9# NaCl and recentrifuged at 10,000 rpm for 10 minutes.
The pellet was taken up again in the saline and centrifuged 
as before. The saline-washed particles were resuspended in 
succinate oxidase assay medium such that 1 ml of the suspen­
sion represented 1 gram (wet weight) of tissue. To 1.9 ml 
of succinate oxidase assay medium that had been air- satur­
ated at 37° C, was added 0.1 ml of saline-washed mitochon­
dria, and 25 |il of 1 (iM cytochrome c in the reaction 
chamber maintained at 37° • oxygen in the reaction mix­
ture (2.0 ml) was titrated by the addition of four 10 |il 
aliqots of 0.0197 M NADH. The oxygen consumption was meas­
ured with a Clark oxygen electrode (Yellow Springs Instru­
ment Co.) polarized to 0.8 V and attached to a Gilson Model 
KM oxygraph. Each addition of NADH produced a pen deflect­
ion on the oxygraph recorder which was directly related to 
to the oxygen content of the solution through the following 
relationships
ng-atom 0 net deflection/reaction 1 ng-atom 0
   -   x   x
reaction average deflection/addition 1 nmol NADH
197 nmol NADH 
addition
The second method utilized the tyrosinase reaction to 
titrate the oxygen content of the reaction volume with L-(-) 
-tyrosine. To 1.9 ml of succinate oxidase assay medium that 
had been air-saturated at 37° C, was added 0.1 ml of tyro­
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sinase solution in the reaction vessel maintained at 37° 0. 
The oxygen in the reaction mixture (2.0) was titrated by 
the addition of three 50|il aliquots of 0.00201 M tyrosine. 
The consumption of oxygen was followed as described for the 
previous method and the oxygen content calculated from the 
following relationship that accounts for the different 
stoichiometry involvedi
ng-atom 0 net deflection/reaction 4 ng-atom 0
    x   x




The standardizations of the NADH and tyrosine solutions 
employed in these procedures are given in Appendix
F. Succinate Oxidase Assay
Succinate oxidase activity was determined following the 
rate of oxygen consumption with the Clark electrode and 
Gilson oxygraph assembly described above. The 2 ml reaction 
chamber, maintained at 37° C, was equipped with ground glass 
closure supplied with a small aperture to allow for the add­
ition of reagents to the chamber without introducing any 
additional oxygen. Various amounts of assay medium (to 
allow for the addition of various other reagents), the suc­
cinate or succinate and disease metabolite solutions were 
added to the reaction vessel. The 100# and 0# oxygen levels 
on the oxygraph were adjusted with appropriate controls and 
0,1 ml mouse liver mitochondria was added to the reaction 
mixture and the chamber was closed. Soon (30-^0 sec) after
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the addition of mitochondria, State 3 oxidation was initiat­
ed with the appropriate addition(s) of 0.00925 M ADP with a 
Hamilton syringe. For some experiments, the metabolites un­
der investigation were added during State ^ following con­
sumption of the first addition of ADP. Additional aliquots 
of ADP was added until the oxygen was depleted.
G. Data Analysis
By extending the tracings produced by the oxygraph 
during each mitochondrial respiration state, the oxygen con­
sumption rate of the succinate oxidase system could be 
calculated from the tangent of the angle (0) the extended 
lines made with the bottom of the recorder paper as shown 
in Figure 4-. It is also necessary to measure the total
pen deflection between the 100$ and 0$ oxygen levels as
this quantity is proportional to the total oxygen available. 
The oxygen consumption rates for the succinate oxidase sys­
tem in States 3 and ^ are obtained from the following rela­
tionships
tan 6 chart speed
reaction rate = ----------------x ----------------  x
pen deflection MLM volume
oxygen content 
protein concentration 
Calculation of the ADP/0 ratio, requires that the State 3 
oxygen uptake be known. This value is found, as shown in 
Figure 4, by measuring the deflection from the initiation 
of State 3 to the beginning of State 4. The ADP/0 ratio was 
calculated as followsi
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M L M ( 0.1 m l ; 17.8  m g  p r o t e i n  /  m l )
B U F F E R  41 i
s u c c i n a t e  |  C H A R T  S P E E D  = 3 0 . 0 m m / m i n
T O T A L  O X Y G E N  = 7 9 7 n g - a t o m s  
A D P
( 7 4 0 n m o l )
1 8 5  m m
1 1 0 m m
7 8 . 0
Figure 4. Oxygraph Tracing Depicting the Extraction of




State 3 pen deflection
x ng-atoms 0
total pen deflection 
The succinate oxidase respiratory parameters were calculated 
from the oxygraph data using the LSU IBM 360/65 computer 
with the FORTRAN program given in Appendix 6.
RESULTS
A. Oxygen Determinations
The titration of the Oxygen content of the 2.0 ml suc­
cinate oxidase assay mixture at 37° C by NADH produced a 
value of 790 ± 2 (mean + standard deviation) ng-atoms 
(198 pM) oxygen from nine determinations. The five tyrosine 
determinations gave a value of 80^ + 1 (mean + standard 
deviation) ng-atoms (201 pM) oxygen. The average of the 
results from the two methods is 797 ng-atoms (199 pM) oxy­
gen. This average value is identical to that reported by 
Chappell in his NADH titrations of dissolved oxygen (9*0*
The concentration of oxygen in air-saturated water at 37° C 
is 225 pM (96). As expected, the concentration of oxygen 
in succinate oxidase assay medium containing 0.25M sucrose 
is lower than that of water alone since the solubility of 
dissolved gases decreases with the amount of solids in solu­
tion (97)- The average value of 797 ng-atoms of oxygen will 
be used as the amount of oxygen dissolved in the reaction 
volume as its concentration corresponds to that reported by 
Chappell (9*0 ■
B. Succinate Oxidation Baseline Parameters
Immediately following the isolation of the mouse liver 
mitochondria, their integrity was verified by a demonstra­
tion of acceptor control of the oxygen consumption rates. 
Each mitochondrial preparation was subjected to three or
3^
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four determinations of acceptor control by three additions 
of 185 nmol of ADP during State 4 respiration as shown in 
Figure 5* Visual verification of an increase in oxygen 
consumption upon the addition of each aliquot of ADP was 
considered to be a sufficient demonstration of acceptor 
control. Calculation of the respiratory parameters at the 
conclusion of the experiment confirmed the validity of this 
practice. The composite values (mean + standard deviation) 
for these determinations are as follows* State 3 oxidation 
rate, 251 ± 29 ng-atoms o/min/mg protein; State 4 oxidation 
rate, 99.0 + 9*3 ng-atoms o/min/mg protein, ACR, 2.57 ± 0.42; 
and ADP/0, 1.62 + 0.20. These values are comparable to 
those reported in the literature. If it was found that a 
particular mitochondrial preparation did not have an ACR of 
at least 2.0, the data obtained from that preparation was 
not used as this is the minimum acceptable level for tightly 
-coupled mitochondria oxidizing succinate (86).
C. Effects of PPA and KIC on Succinate Oxidation Initiated 
bv Additions of 186 Nanomoles of ADP
In this series of experiments, succinate or succinate 
plus KIC or PPA were added to the assay buffer prior to the 
MLM. Following the addition of the MLM, 185 nmol aliquots 
of ADP were introduced into the reaction mixture to produce 
three State 3 - State 4 cycles as shown in Figure 5- Other 
conditions were as previously described. The effects of 
PPA on succinate oxidation initiated by three additions of 











111 n g - a t o m s  0
I min
Figure 5» Oxygraph Tracing Showing the Initiation of
State 3 Succinate Oxidation by Three Additions of 
185 Nanomoles of ADP.
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Table 3. The State 3 respiration rate was not significantly 
reduced by 7.5 mM PPA. The State ^ respiration rate was 
increased by 2Q%>, thus causing a reduction of the ACR by 
23.2%. The ADP/O ratio was reduced by 19-9% in the presence 
of PPA. Under the same conditions, as shown in Table 7*5 
mM KIC had no appreciable effect upon succinate oxidation.
By conditioning the mitochondria with a 185 nmols addition 
of ADP before adding the KIC as shown in Figure 6, effects 
on succinate oxidation could be observed. For the controls, 
assay medium was added following conditioning. In Table 5 
it can be seen that with conditioned mitochondria, there 
was no significant reduction in the State 3 respiration 
rate, but the other parameters were affected in the same 
manner as the unconditioned mitochondria by PPA, The State 
k respiration rate was elevated lk% which lowered the ACR 
by 26.3%. KIC reduced the ADP/O ratio by ?,k%,
D. Effects of PPA and KIC on Succinate Oxidation Initiated 
bv ^63 Nanomoles of ADP in Conditioned Mitochondria
The mitochondria were conditioned by the addition of 
185 nmols of ADP prior to the initiation of State 3 oxida­
tion with ^63 nmols of ADP as shown in Figure 7* The con­
trols were treated in a like manner with an equal volume of 
assay buffer. The increased amount of ADP used to initiate 
State 3 oxidation produced an increase in the control values 
for the State 3 respiration and thus the ACR*s. These in­
creases are evident from the comparison of the control 
values from Tables 3 and ^ with those of Tables 6 and 7«
TABLE 3
The Effects of PPA on Succinate Oxidation Initiated by 185 Nanomoles of ADP*
Control PPA # Control t-test**
State 3 Respiration Rate
(ng-atoms O/min/mg protein)
258 + 13 236 + 12 91.5 NS
State ^ Respiration Rate
(ng-atoms O/min/mg protein)
123 + 5 148 + 18 120 S
Acceptor Control Ratio 2.07 + 0.16 1.59 ± 0.17 76.8 S
ADP/O Ratio l.kl ± 0.19 1.13 + 0.03 80.1 S
* pH 37°C, 7*5 mM succinate, 7*5 mM PPA
** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference
TABLE 4
The Effects of KIC on Succinate Oxidation Initiated by 185 Nanomoles of ADP*
Control KIC # Control t-test**
State 3 Respiration Rate
(ng-atoms o/min/mg protein)
251 ± 10 252 + 16 100 NS
State 4 Respiration Rate
(ng-atoms O/min/mg protein)
99.9 ± 6,1 110 + 11 110 NS
Acceptor Control Ratio 2.57 + 0.14 2.38 + 0.28 92.6 NS
ADP/O Ratio 1.58 + 0,07 1.46 + 0.09 92.4 NS
*pH 7.4, 37°C, 7.5 succinate, 7-5 mM KIC
**NS - no significant difference at the 95# confidence level from Student's
t distributions
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Figure 6. Oxygraph Tracing Showing the Conditioning of the
Mitochondria by 185 Nanomoles of ADP Prior to the 
Addition of the a-Ketoacids.
TABLE 5
The Effects of KIC on Succinate Oxidation 
Initiated by 185 Nanomoles of ADP in Conditioned Mitochondria*
Control KIC # Control t-test**
State 3 Respiration Rate
(ng-atoms O/min/mg protein)
283 ± 10 273 ± 16 96.5 NS
State 4 Respiration Rate
(ng-atoms o/min/mg protein)
86.3 ± 4.2 98.7 ± 5-4 114 S
Acceptor Control Ratio 3.32 + 0.11 2.78 + 0.11 83.7 S
ADP/O Ratio I .63 + 0.06 1.51 ± 0.04 92.6 S
* pH 7.4, 37°C, 7*5 mM succinate, 7*5 mM KIC
MLM were conditioned with an addition of 185 nmols of ADP prior to the addition 
of KIC
** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference
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Figure 7. Oxygraph Tracing Showing the Conditioning of the 
Mitochondria by 185 Nanomoles of ADP Prior to the
Initiation of State 3 Oxidation by ^63 Nanomoles of ADP.
TABLE 6
The Effects of PPA on Succinate Oxidation 
Initiated by 463 Nanomoles of ADP in Conditioned Mitochondria*
Control PPA # Control t-test**
State 3 Respiration Rate 32k ± 29 260 + 28 80.4 S
(ng-atoms O/min/mg protein)
State 4 Respiration Rate 87.2 ± 12.3 128 + 8 14? S
(ng-atoms O/min/mg protein)
Acceptor Control Ratio 3.72 ± 0.44 2.04 + 0.21 5k. 7 S
ADP/O Ratio 1.61 + 0.09 1.42 + 0.06 88.2 S
* pH 37°C» 7*5 mM succinate, 7-5 mM PPA
MLM were conditioned with an addition of 185 nmols of ADP prior to the addition 
of the PPA




The Effects of KIC on Succinate Oxidation 
Initiated "by ^63 Nanomoles of ADP in Conditioned Mitochondria*
Control KIC % Control t-test**
State 3 Respiration Rate 338 + 16 3^8 + 17 103 NS
(ng-atoms O/min/mg protein)
State ^ Respiration Rate 89.1+ + 5*3- 109 ± 13 122 S
(ng-atoms O/min/mg protein)
Acceptor Control Ratio 3.79 ± 0.20 3.21 + 0.25 8^.7 S
ADP/O Ratio 1.65 + 0.07 1.51 ± 0.03 91.5 S
* pH 7-^i 37°C, 7-5 mM succinate, 7*5 mM KIC 
MLM were conditioned with an addition of 185 nmols of ADP prior to the addition of 
the KIC
** 95# confidence level from Student*s t distributions
NS - no significant difference; S - significant difference
**5
Table 6 shows the effects of PPA on succinate oxidation in 
this system. PPA decreased the State 3 respiration rate by 
19*6# while increasing the State b rate by ^7%. These 
changes are reflected in the ACR which was lowered by ^5*3$ 
in the presence of PPA. The ADP/O ratio was also decreased 
by 11.8$. As can be seen in Table 7» KIC had no effect on 
the State 3 respiration rate under these conditions. The 
State 4 respiration rate was increased by 22%. The ACR and 
ADP/O ratio were reduced 15*3^ and 8»5$» respectively.
E. Effects of PPA and KIC on Succinate Oxidation Initiated 
bv the Addition of 7^0 Nanomoles of ADP
In this study, the PPA and KIC were added to the assay 
medium prior to the introduction of the mitochondria. Fol­
lowing the addition of the mitochondria, a single State 3 - 
State k oxidation cycle was initiated with 7^0 nmols ADP, 
as shown in Figure 8. Neither PPA nor KIC significantly 
affected the State 3 respiration rates and ADP/O ratios as 
seen in Tables 8 and 9- raised the State ^ respiration
rate 39% while KIC increased it 3Q%>» The ACR's were reduced 
by PPA and KIC by 38*7$ and 22.6%, respectively.
F. The Effects of Increasing PPA and KIC Concentrations 
on the Succinate Oxidase Accentor Control Ratios
The ACR's were determined from a series of experiments 
in which the PPA concentrations were 0.25 mM, O.63 mM,
2.5 mM, 5»° mM, and 7.5 mM. State 3 oxidation was initiated 
with ^63 nmols of ADP after conditioning and the addition of 
PPA as shown in Figure 7* With increasing concentrations
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Figure 8. Oxygraph Tracing Showing the Initiation of State 3
Oxidation by the Addition of 7^0 Nanomoles of ADP.
TABLE 8
The Effects of PPA on Succinate Oxidation Initiated "by 740 Nanomoles of ADP*
Control PPA % Control t-test**
State 3 Respiration Rate
(ng-atoms O/min/mg protein)
363 + 24 311 + 34 85.7 NS
State 4 Respiration Rate
(ng-atoms O/min/mg protein)
84.2 + 7.5 117 ± 7 139 S
Acceptor Control Ratio 4.32 + O .33 2.65 + 0.43 61.3 S
ADP/O Ratio 1.66 + 0,20 1.60 + 0.21 96.4 NS
* pH 7.4, 37°C, 7-5 mM succinate, 7*5 mM PPA
** 95# confidence level from Student’s t distributions
NS - no significant difference; S - significant difference
TABLE 9
The Effects of KIC on Succinate Oxidation Initiated "by 740 Nanomoles of ADP*
Control KIC # Control t-test**
State 3 Respiration Rate
(ng-atoms o/min/mg protein)
359 ± 15 359 ± 15 100 NS
State 4 Respiration Rate
(ng-atoms O/min/mg protein)
84.6 + 4.2 110 + 7 130 S
Acceptor Control Ratio 4.25 ± 0.22 3.29 ± 0.33 77.4 s
ADP/O Ratio 1.59 ± 0.12 1.44 +. 0.09 90.6 NS
* pH 7.4, 37°C, 7-5 mM succinate, 7-5 mM KIC
** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference
of PPA, the ACR's were reduced in a non-linear fashion as 
seen in Figure 9» with the majority of the reduction occur­
ring below 1 mM, The effects of KIC at 2.5 mM, 5*0 mM, and
7.5 mM on ACR were determined from the two State 3 “ State b 
cycles initiated by 185 nmols of ADP following conditioning 
and the addition of KIC as shown in Figure 6. The ACR’s 
for succinate oxidation in the presence of increasing concen 
trations of KIC measured in this manner decrease in an al­
most linear fashion as shown in Figure 10. The relative 
effectiveness of PPA and KIC in reducing the ACR as their 
concentrations are increased is shown in Figure 11 (Care 
should be taken in any attempted comparisons of the effects 
of PPA and KIC from Figure 11, as the effects of each metab­
olite were determined under different conditions).
G. Effects of Other Compounds on Succinate Oxidation
The other BCKU a-ketoacids (KIV and KMV) and the pyr­
uvate transport inhibitor (CHC) did not appear to have any 
appreciable effect upon succinate oxidation, based on the 
limited data obtained. Representative data from the use of 
these compounds is provided in the computer printout given 
in Appendix 6.
H. Oxygen Consumption by cc-Ketoacids
The a-ketoacids employed in this study did not affect 
the oxygen consumption when they were used as substrates 
for mitochondrial respiration under the conditions described 
Thus, it was not necessary to correct the data to account 
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Figure 11. Relative Effectiveness of Various Concentrations 
of PPA and KIC in Reducing the Acceptor Control Ratio.
DISCUSSION
It has been shown that the initial State 3 mitochondrial 
respiration rates are usually less than those observed 
following several State 3 - State k cycles (98). Mitochon­
dria may be relieved of this inhibition by incubating 
them with substrate and subjecting them to several State 3- 
State 4 transitions with ADP. Removal of the initial 
depression of State 3 respiration in mitochondria has been 
termed conditioning (99). This inhibition is thought to be 
a result of the isolation process. From the data presented 
in Tables 3 and 9i it can be seen that there was no effect 
upon the State 3 respiration rates in the presence of PPA. 
Only when the mitochondria had been conditioned with the 
prior addition of ADP did PPA reduce the State 3 respira­
tion rate. This supports the contention of Raison et al. 
that the initial inhibition of State 3 respiration must 
be removed by conditioning before another type of inhibition 
can be observed (98#99)- Under no conditions employed in 
this investigation did KIC affect the State 3 respiratory 
rate of either conditioned or unconditioned mitochondria.
This is taken as evidence that PPA is a more potent effector 
of mitochondrial respiration than is KIC.
While the effects of KIC on succinate oxidation under 
the conditions employed in acquiring the information in 
Table ^ were not statistically different from the controls,
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the presence of the KIC produced a trend sufficiently 
analogous to that of PPA to encourage further investigation# 
By subjecting the mitochondria to one conditioning cycle 
which was not used tn the compilation of the data, the 
control values for all four respiratory parameters were 
improved, The State 3 respiration rate was increased while 
the State ^ rate was somewhat diminished. This resulted in 
a higher ACR, indicating that the mitochondria were more 
tightly coupledo The increase in the ADP/O ratio meant that 
the efficiency of oxidative phosphorylation was enhanced by 
the conditioning cycle. With the improved control values 
it was easier to detect changes in mitochondrial respiration 
due to the presence of KIC.
It was also stated that two or more State 3 - State 4 
cycles using small additions (180 nmols) of ADP were more 
effective in overcoming the initial inhibition of State 3 
respiration than one large addition (900 nmols) of ADP (98). 
This can also be seen when comparing the controls of Table 5 
with those of Tables 3 ami In studies on the effects of 
a-ketoacids on pyruvate, P-hydroxybutyrate, and acetoacetate 
oxidation in rat brain mitochondria, Clark et al. showed 
that one conditioning cycle initiated by 500 nmols of ADP 
gave good results when it was followed by a similar addition 
after the introduction of the a-ketoacids during the inter­
vening State k period (29#32*^5»58). For the studies 
described in Tables 6 and 7, it was found that a single 
conditioning cycle with 185 nmols of ADP also gave good
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control values when it was followed "by an addition of 463 
nmols of ADP after the introduction of PPA or KIC during 
the intervening State 4 period. It would appear that there 
is more than one way to overcome the intrinsic inhibition 
of State 3 respiration imparted to mitochondria by the iso­
lation procedure. In fact, the variation between the iso­
lation procedures, the buffer systems employed, and the 
source of mitochondria may all affect the magnitude, 
duration and measures required to remove the depression of 
respiration rates following the isolation of mitochondria.
There are no comparable data from a mammalian system 
for that given in Tables 6 and 7* In this study PPA was 
shown to inhibit State 3 succinate respiration by 20$.
PPA (5 mM) has been reported to inhibit State 3 succinate 
respiration in yeast mitochondria by 21$, while no inform­
ation was provided for State 4 respiration, ACR, or ADP/O 
ratios (100). The study on yeast mitochondria also reported 
that CHC (50 pM) and KIC (5 mM) had no effect on State 3 
succinate oxidation which is also substantiated by this 
investigation in Appendix 6 and Table 7* As before there 
was no information given on the effects CHC and KIC had on 
the other parameters of succinate oxidation in yeast 
mitochondria.
While the data from Clark’s laboratory regarding the 
effects of the BCKU and PKU metabolites on pyruvate, 
P-hydroxybutyrate, and acetoacetate oxidation in rat brain 
mitochondria cannot be directly compared with the results
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of this study, it is worthwhile to note the similarities 
and differences as both investigations are addressing the 
same problem. In rat brain mitochondria oxidizing pyruvate,
2 mM PPA reduced State 3 respiration 55$» had no effect on 
State 4 respiration, and reduced the ACR 52$ (^5)* In the 
same system, 2 mM KIC inhibited State 3 respiration 37%, 
increased the State ^ respiration rate 28$, and reduced 
the ACR 51$. When tested with rat brain mitochondria oxi­
dizing P-hydroxybutyrate, PPA reduced State 3 respiration 
36$, increased the State ^ rate 12$, and lowered the ACR
by ^3$• KIC followed the same pattern as PPA in its effects 
on P-hydroxybutyrate oxidation. The State 3 rate was 
inhibited 29$, the State b rate elevated 12$, and the ACR 
reduced 36$. In this study on mouse liver mitochodrial 
succinate oxidation, the effects of PPA were not as pro­
nounced yet they followed the same trend. The KIC effects 
described in Table 7 for succinate oxidation were not as 
great as those reported for the NAD-linked substrates and 
KIC evoked no change in the State 3 respiration rate.
In order to ascertain whether or not the initial State
3 inhibition could be overcome by the addition of a large 
amount of ADP, studies on the effects of PPA and KIC on 
succinate oxidation initiated with ?40 nmols of ADP in 
unconditioned mitochondria were undertaken. As seen in 
Tables 8 and 9 the control values for the State 3 respira-r 
tion rates were higher than those of the previous studies 
and the State 4 rates were lower. These rates produced the
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highest ACR values reported and the ADP/O ratios were 
consistently high also. It is evident from this information 
that the conditioning described above is not necessary for 
this particular system. However, it can be seen from a 
comparison of the effects of PPA on conditioned and uncon­
ditioned mitochondria that conditioning provides a better 
opportunity to observe significant changes in the State 3 
respiration rate and the ADP/O ratio. As for the condition­
ing studies described above, there is no similar data 
available for comparison with this technique. The only 
other study which employed large quantities of ADP to start 
State 3 oxidation was that of Halestrap et al. (31)» where­
in the effects of PPA and KIC on rat brain pyruvate oxida­
tion are reported. PPA and KIC were introduced into their 
reaction mixture following initiation of State 3 with the 
addition of 5000 nmols of ADP/ml. They reported only that 
5 mM PPA and KIC inhibited State 3 oxygen consumption 
rates by 57% and 41 fo, respectively. No details of the 
State 3 respirations rates were given and by their method, 
no State 4 rates could be obtained. It is assumed that 
their use of such an enormous quantity of ADP was utilized 
so as to approximate the State 3 rate thought to occur 
in vivo.
In order to determine the sensitivity of the ACR as 
a measure of mitochondrial integrity, the effects of in­
creasing concentrations of PPA and KIC on the ACR was studied. 
Figure 9 clearly shows that the effect of PPA on succinate
oxidation and mitochondrial integrity can be observed at 
concentrations below 1 mM. The effect of KIC can begin 
to be seen at 2.5 mM. These observations are at odds with 
the statement of Land and Clark that there was no effect on 
succinate oxidation by PPA and KIC in this concentration 
range (32).
Again with the saveat that the ACR's were determined 
using differing quantities of ADP to initiate State 3 
respiration, it may be cautiously inferred from the relative 
effectiveness of PPA and KIC in reducing the ACR's of suc­
cinate oxidation as shown in Figure 11, that PPA is a more 
powerful disruptor of mitochondrial integrity. This impli­
cation is supported by the other information presented in 
this investigation. Under all conditions employed PPA 
increased the State 4 oxidation to a greater extent than 
KIC and thus reduced the ACR's more than did KIC. In the 
conditioned mitochondria PPA also lowered the ADP/O ratios 
more than KIC did and PPA also inhibited State 3 respiration 
whereas KIC did not. It is concluded that this greater 
effect upon succinate oxidation by PPA is due to its aro­
matic character. Indeed, aromatic compounds have been 
shown to be more efficient inhibitors of mitochondrial oxi­
dation than aliphatic ones and this phenomenon has been 
attributed to the greater affinity of aromatic compounds to 
bind to the hydrophobic sites of the electron transport 
system (101).
A final comment on the comparison of the results of
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this work with those of other investigators is in order.
The temperature employed in this investigation was 37° C 
while that used in the studies from Clark's laboratory was 
25° C (32,^5). Succinate oxidase activity measured polaro- 
graphically exhibits a discontinuity in its Arrhenius plot 
in the range of 23-25° C (102). Discontinuities in the 
Arrhenius plot of a membrane-bound enzyme system may be 
due to a change in the rate-limiting step of the reaction 
it catalyzes or a change in the enzyme conformation due to 
a lipid phase transition in the membrane environment of 
the enzyme (103»10^). As the succinate oxidase complex 
and the entire electron transport system are integral 
membrane proteins, any change in their membrane environment 
due to temperature or other factors would be expressed in the 
respiratory parameters observed polarographically. It has 
been shown that rat liver mitochondrial membranes undergo 
a lipid phase transition from a gel-like solid below 23° C 
to a liquid crystalline state above 25° C (10^). Any 
measurements of respiratory characteristics would likely 
contain kinetic contributions due to the presence of both 
lipid phases in this temperature range. Interpretation of 
data so obtained would have to be done with care and the 
extrapolation of any effects observed to a physiological 
condition should be made with caution. The results of the 
studies described in this report are free of any complica­
tions involved with lipid phase transitions since they 
were obtained well above the transition temperature in the
6o
linear region of the Arrhenius diagram.
There are several implications of the results of this 
work that can he related to the general depression of energy 
metabolism evident in phenylketonuria and branched-chain 
ketonuria. The inhibition of State 3 respiration by a level 
of PPA known to occur in PKU in conditioned mitochondria, 
and the trend in that direction in unconditioned mitochon­
dria, indicates that electron transport and concomitant ATP 
production could be reduced in the diseased state. The 
elevation of State ^ respiration rate by both PPA and KIC 
shows that the presence of these compounds allows electron 
transport to proceed even in the absence of a phosphate 
acceptor. In other words, PPA and KIC induce a loss of 
phosphate acceptor control over electron transport. This 
means that the electron transport system is proceeding with 
the reduction of oxygen without any production of metaboli- 
cally useful energy. PPA and KIC promote appreciable re­
ductions in the acceptor control ratios in conditioned 
mitochondria and in unconditioned mitochondria whose State 3 
respiration is initiated with a large quantity of ADP (i.e., 
greater than 185 nmols). As discussed before, the ACR may 
be taken as a measure of mitochondrial membrane integrity. 
The reduction of the succinate oxidation ACR supports the 
suggestion that PKU and BCKU metabolites disrupt internal 
mitochondrial structure as observed in electron micrographs 
(36,37)- The reduction in the ADP/0 ratios observed in the 
presence of PPA and KIC in conditioned mitochondria shows
6l
that these compounds decrease the efficiency of oxidative 
phosphorylation. The reduced ADP/O ratios demonstrate that 
a greater amount of oxygen is being consumed to phosphorylate 
ADP' in the presence of PPA and KIC than is normally required.
These effects of PPA and KICT on succinate oxidation are 
interpreted as a demonstration that these metabolites which 
accumulate in PKU and BCKU act as uncouplers of oxidative 
phosphorylation and thus responsible in part for the symp­
toms observed. It would seem that the method by which the 
uncoupling occurs is a direct result of a partial disruption 
of inner mitochondrial membrane. A partially disorganized 
inner membrane would then become leaky to protons. Protons 
re-entering the mitochondrial matrix would tend to dissipate 
the proton gradient formed by electron transport. The pro­
ton gradient is required by the chemiosmotic theory to pro­
vide the driving force for the phosphorylation of ADP to 
ATP by F^- ATPase (81,105)i PPA would further contribute 
to the diminution of the proton by inhibiting its formation 
by the electron transport system. From this discussion it 
can be seen that the depressed energy metabolism in PKU 
and BCKU is, at least in part, due to the lessened effi­
ciency of oxidative phosphorylation. It cannot be stated 
that the effects of PPA and KIC seen in these studies are of 
a sufficient magnitude to account for all the symptoms ob­
served in PKU and BCKU.
In the introductory remarks, it was surmised that the 
inhibition of several key mitochondrial transport systems by
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PPA and KIC was a major contributing factor in the diminish­
ed energy metabolism in PKU and BCKU. This does not now 
appear to be the case because a reappraisal of the techniques 
previously used to measure pyruvate transport was reported 
during the preparation of this work. It was demonstrated 
that most of what had been called pyruvate transport was 
merely adsorption onto the mitochondrial membrane (106).
The remainder was shown to be pyruvate transport by a modi­
fied method and it was also inhibited by CHC. The inhibi­
tion of pyruvate transport by PPA and KIC was shown to be 
competition for the nonspecific adsorption sites on the 
mitochondrial membrane. With the new method, PPA and KIC 
did not affect pyruvate transport at a concentration of 
1 mM. It remains to be seen whether or not higher concen­
trations of PPA and KIC adversely affect pyruvate or any 
other monocarboxylate transporter system.
With this new information concerning pyruvate trans­
port comes the question of whether or not PPA and KIC are 
actually transported across the inner mitochondrial mem­
brane as reported earlier (38i39»^0»55)• There is no evi­
dence to preclude the diffusion of KIC and PPA across the 
membrane into the matrix space as do acetoacetate and 
(3-hydroxybutyrate (106). It may even be possible for pyr­
uvate to enter the mitochondria by diffusion once the 
transporter mechanism has been saturated. It is concluded 
that the abnormally high levels of a-ketoacids produced 
in PKU and BCKU allow them to inhibit specific enzyme
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reactions involved in energy-related metabolism as well as 
to enter the mitochondrial membrane and matrix to partially 
uncouple oxidative phosphorylation. The proposition that 
the chronic and acute symptoms of PKU and BCKU are the re­
sult of cumulative effects of the diseased-state metabolites 
is supported by the wealth of evidence presented in Table 1 
and summarized in Figure 12. The need for another Krebs 
cycle reaction to be affected by PPA and KIC (*l4) is satis­
fied by the inhibition of citrate synthase (2^,29)» Figure 
12 shows what are considered to be the major common effects 
observed due to the presence of the PKU and BCKU a-ketoacids. 
Other reactions that are affected by metabolites of either 
PKU and BCKU are also shown. It should be reiterated that 
there is no one reaction or metabolic system that is total­
ly blocked by the metabolites produced in each genetic 
disease. It is the cumulative effects of the disease-state 
metabolites that are considered to produce the clinical 
manifestations of PKU and BCKU. The similarity in the symp­
toms observed in both disorders is due to the metabolites 
produced by each genetic disorder affecting similar meta­
bolic systems.
For normal growth and development, a source of energy, 
a source of reducing power, and biosynthetic precursors 
are required. In PKU and BCKU the normal levels are all 
diminished. Energy production is reduced by the reduced 
flux of metabolites through glycolysis and Krebs cycle.
This is accomplished through the inhibition of pyruvate
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Figure 12. Sites of Inhibition by PKU and BCKU Metabolites. 
* PKU only 
^ BCKU only
^ reported in this investigation
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kinase, pyruvate dehydrogenase, citrate synthase and a-keto- 
glutarate dehydrogenase. The reduction of ATP production 
due to these inhibitions is further aggravated by partial 
uncoupling of oxidative phosphorylation. The inhibition 
of citrate synthase is also responsible for a loss of 
reducing power in the form of NADPH. With the reduction 
in citrate production there is a concomitant loss in the 
amount of cytosolic isocitrate available for regeneration 
of NADPH form NADP by isocitrate dehydrogenase. The avail­
ability of NADPH is further reduced in PKU due to the inhi­
bition of 6-phosphogluconate dehydrogenase. The inhibition 
of pyruvate dehydrogenase directly curtails the amount of 
acetyl-Coenzyme A available for the biosynthesis of the 
lipids required for myelin deposition around nerve tissues. 
The level of acetyl-Coenzyme A is also reduced by the inhi­
bition of citrate synthase. The biosynthesis of other 
myelin components are also inhibited. Sterols and long- 
chain fatty acids are not produced in sufficient amounts 
for normal myelination to occur due to the inhibition of 
fatty acid synthase and a deficient supply of energy and 
NADPH. The incorporation of galactose into the cerebrosides 
of myelin is also depressed. The reduction of protein and 
nucleic acid synthesis is probably due to the lack of energy 
and reducing power. All these factors are considered to be 
contributory to the depressed myelination observed in PKU 
and BCKU. The defective myelination of the nervous tissue 
results in the characteristic mental retardation seen in
phenylketonuria and branched-chain ketonuria.
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A ..............  adrenal
AcAC ..........  acetoacetate
AcAc-CoA........ acetoacetyl-Coenzyme A
Ac-CoA ........  acetyl-Coenzyme A
ACR ............  acceptor control ratio
ADP ............  adenosine 5*-diphosphate
ADP/O . . . . . .  ADP phosphorylated per oxygen consumed
A L A ............ alanine
A S P ............ aspartate
A T P ..........  . adenosine 5*-"triphosphate
B .............. brain
BCKA . . . . . .  branched-chain oc-ketoacids
BCKU ..........  branched-chain ketonuria
B1.............. blood
BSA ............  bovine serum albumin
C ..............  Celsius
C^gFA ..........  any fatty acid containing sixteen carbons
CHC . . . . . . .  a-cyano-it-hydroxycinnamic acid
C I T ............ citrate
C o A ............ Coenzyme A
E ..............  erythrocyte
EDTA ..........  ethylenediamine tetraacetic acid
EGTA ..........  ethyleneglycol-bis (P-aminoethyl ether)-
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N,N'-tetraacetic acid 
F^-ATPase . . . .  mitochondrial enzyme phosphorylating
ADP to ATP
F b .......... .. fibroblast
G A L ............ galactose
G L U ............ glutamate
G-6-P ..........  glucose-6-phosphate
H .............. heart
KEPES ..........  N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid
H P A A .......... o-hydroxyphenylacetic acid
I C I T .......... isocitrate
l i e ............ isoleucine
K ..............  kidney
aKA .  ......... a-ketoacid
aKG ............  a-ketoglutarate
KIC . . . . . . .  a-ketoisocaproate
KIV ............  a-ketoisovalerate
Km ............  Michaelis constant
KMV ............  a-keto-0-methylvalerate
L .............. liver
........  . . microliter
LAC . . . . . . .  lactate
L b ............ lymphoblast
Leu . . . . . . .  leucine
| i M ............ micromolar
M ............ .. molar (moles per liter)
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M A L .........malate
MAL-CoA ........  malonyl-Coenzyme A
m g ....... milligram
m i n ......... minute
m l .......milliliter
MLM ............  mouse liver mitochondria
m m ....... millimeter
m M ....... millimolar
MSUD . . . . . .  maple syrup urine disease (branched-chain
ketonuria)
NAD ............  nicotinamide adenine dinucleotide,
oxidized form
NADH ..........  nicotinamide adenine dinucleotide,
reduced form
NADP ..........  nicotinamide adenine dinucleotide
phosphate, oxidized form
NADPH ..........  nicotinamide adenine dinucleotide
phosphate, reduced form
n g ........ nano gram
n m o l ...... nanomole
0 ............  . atomic oxygen
O A A ....... ..... oxaloacetate
p-OH-B . . . . .  p-hydroxybutryate
P . . . . . . .  . pancreas
P A A ... phenylacetic acid
P E A .... phenylethylamine
PEP . . . . . . .  phosphoenolpyruvate
6-P-G . . . . . .  6-phosphogluconate
p H ............ negative logarithm of the hydrogen ion
concentration 
Phe . . . . . . .  phenylalanine
Pi ............  orthophosphate
PKU ............  phenylketonuria
P L A ............ phenyllactic acid
P/0 ............  phosphate consumed per oxygen consumed
PPA ............  phenylpyruvate
PYR .  ......... pyruvate
rpm . . . . . . .  revolutions per minute
Ru-5-P ........  ribulose-5-phosphate
S U C ..............succinate
TRIOSE-P . . . .  triose phosphate 
V a l ............ valine
APPENDIX 2
The Coupling of a-Cyano-4-hydroxycinnamic Acid to Agarose
Fifteen ml bromoacetamidohexylagarose freshly prepared 
according to March et al. was washed with 50 ml of 0.1 M 
NaHCO^ (pH 9*5)- The wash solution was removed by suction 
and the packed gel was added to 0.2 mole of a-cyano-4- 
hydroxycinnamic acid (CHC) in 20 ml dioxane. The pH was 
adjusted to 9*5 and the reaction was allowed to proceed at 
room temperature for 3 days with constant agitation. The 
pH was monitored periodically and readjusted to 9-5 as 
nescessary. After 3 days the dioxane solution was removed 
by suction and the gel was mixed with 30 ml of 0,2 M mer- 
captoethanol in 0.01 M NaHCO^ (pH 9*5) for 2 hours at room 
temperature to block any unreacted bromoacetyl groups. 
Following the mercaptoethanol treatment, the gel was washed 
with 200 volumes of 0.2 M NaCl and then with 200 volumes of 
water. This procedure was patterned after the procedure 
employed by Cuatrecasas to link estradiol through its 
hydroxyl function to bromoacetamidohexylagarose.
To determine the amount of CHC bound to the agarose,
0.2 ml of the packed gel was solubilized according to the 
method of Failla and Santi. The solubilized CHC-agarose 
exhibited a Xmax of 280 nm as compared to that of the free 
CHC of 32^ nm. This spectral shift is indicative of attach­
ment through the hydroxyl function of CHC. The amount of
80
CHC bound was estimated to be 230 nmol/ml of packed gel 
using Beer's law and the molar extinction coefficient of 
p-methoxycinnamic acid (23,7°0 M ^) (Sadtler Standard Spec 
tra). The proposed structure of the agarose derivative is 
given in Figure 1-A.
Appendix 2 References 
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A. Adenosine V  -Drphosohate (0.0925 M)
One gram of barium ADP was dissolved in a minimum 
volume of 0.01 M KPi buffer (pH6.8) and the barium was pre­
cipitated with an equimolar quantity of sodium sulfate.
The BaSO^ precipitate was removed by centrifugation. The 
supernatant was decanted and taken up to 70 ml to give an 
approximately 0.1 M ADP solution. The determination of the 
actual 0.0925 molarity is given in Appendix
B. Biuret Reagent
To 500 ml of water were added 1.5 g of CuS0^‘5H2O and 
6.0 g of NaKC^Og'^HgO. This solution was added to 300ml of 
10fo (w/v) NaOH and then made up to 1 liter with water.
C. Bovine Serum Albumin
One hundred mg of BSA were dissolved in water and made 
up to 10.0 ml to give a standard protein solution with a 
concentration of 10.0 mg/ml.
D. q-Cvano-^-hvdroxvcinnamic Acid (0.1 M)
This solution was prepared by taking 0,1892 g of CHC 
up to 10.0 ml in absolute ethanol.
E. Cytochrome c (1.0 11M)
Ten pi of 0,000815 M equine cytochrome c (12,270 dal- 




F. Disease Metabolite Stock Solutions
Stock solutions of 0.25 M KIC, KIV, KMV, and PPA in 
the succinate oxidase assay medium were prepared weekly from 
the sodium salts and stored frozen.
G. 3-Nicotinamide Adenine Dinucleotide. Reduced Form 
(0.0197 M)
About 15 mg of P-NADH were dissolved in 1 ml succinate 
oxidase assay medium to give an approximately 0,02 M {3-NADH 
solution. The determination of the actual 0.0197 molarity 
is given in Appendix 4.
H. Mouse Liver Mitochondria Isolation Medium
The MLM isolation medium was composed of 0.25 M sucrose, 
0.001 M HEPES, and 0.001 M EGTA. The pH was adjusted to 7*4 
at 4° C with K0H.
I. Potassium Phosphate Buffers (0.1 M)
Tenth molar solutions of the monobasic and dibasic 
potassium salts were mixed in various proportions to pro­
duce the 0.1 M KPi buffers of the required pH values.
J. Succinate Stock Solution
A stock solution of 0.5 M succinate was prepared in 
water from the free acid. The acid was neutralized and 
the pH adjusted to 7.4 with K0H.
K. Succinate Oxidase Assay Medium
The succinate oxidase assay medium was composed of 
0.25 M sucrose, 0,01 M KPi (100 ml of 0.1 M KPi buffer, 
pH 7.4 per liter), 0.001 M HEPES, 0.001 M EGTA, and 0.005 M 
MgClg. The pH was adjusted to 7*4 at 37° C with K0H.
L. Triton - Urea Reagent
Four ml of Triton X-100 were added to 100 ml of satu­
rated urea to give a 4# (v/v) Triton - urea solution,
M. Tyrosinase Solution
Crystalline tyrosinase (2750 units/mg) was dissolved 
in succinate oxidase assay medium to yield a solution with 
an activity of 10,000 units/ml. One unit of tyrosinase 
causes an increase in absorption at 280 nm of 0.00l/min 
at pH 6.5 at 25°C in a 3^0 ml reaction volume containing 
L-(-)-tyrosine.
N. Tvrdsine (0.00201 M)
L-(-)-Tyrosine was made up in succinate oxidase assay 
medium to be approximately 0.002 M. The determination of 
the actual 0.00201 molarity is given in Appendix 4.
APPENDIX k 
Assays of Titrant Solutions
A. Adenosine V  - Diphosphate
Five aliquots of the approximately 0.1 M ADP solution 
were diluted $000 fold in 0.01 M KPi (pH The absorp­
tion of these solutions was measured at 259 nm on a Cary l̂J- 
spectrophotometer and their molarities were calculated 
using Beer's Law and a molar extinction coefficient of 
15,^00 M . After correcting for the dilution, the concen­
tration of the original solution was determined to be 
0.0925 + 0.0001 M (mean + standard deviation) .
B. g-Nicotinamide Adenine Dinucleotide. Reduced Form
Five aliquots of the approximately 0.02 M NADH solution 
were diluted 1250 fold with 0.01 M KPi (pH 7-*0. The opti­
cal density of the dilutions were measured on a Cary 1^ 
spectrophotometer at 260 nm. Using Beer's Law and the molar 
extinction coefficient of 6250 (taken from the NADH pro­
duct brochure supplied by SIGMA Chemical Co.), the molari­
ties of the dilutions were calculated. The concentration 
of the original NADH solution was found to be O.OI97 +
0.0002 M (mean + standard deviation) after correcting for 
the dilution.
C. L-(-)-Tvro sine
Five aliquots of the approximately 0.002 M tyrosine 
solution were diluted 10 fold in 0.01 M KPi (pH 7»^). The
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absorption of these dilutions were determined at 275 nm on 
a Cary 1^ spectrophotometer and their molarities were cal­
culated using Beer's Law and a molar extinction coefficient 
of 1^13 M-'*’. After correcting for the dilution, the concen­
tration of the original tyrosine solution was determined to 
be 0,00201 + 0.00002 M (mean + standard deviation).
Appendix 4 References 
Robinson, J. W, (ed.) (197*0 Handbook of Spectroscopy,
Vol. II, Chemical Rubber Company, Cleveland, Ohio, 
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Figure 2-A. Biuret standard curve.
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APPENDIX 6 *
C01 PROGRAM COMPUTES MLM OXYGEN CONSUMPTION RATES (NANOGRAM-ATOM O/MIN/MG 
C PROTEIN) IN STATES 3 & if-, ACCEPTOR CONTROL RATIO (ACR) & ADP/O
C RATIO FROM OXYGRAPH DATA. AVERAGE DEVIATION (AVG. DEV), STANDARD
C DEVIATION (STD DEV) & fo CONTROL (fo  CON) ARE CALCULATED FROM EACH
C MLM PARAMETER.
1 DIMENSION S3 (35.3). S4 (35.3). PO (35.*0. CW (35), ACR (35), ADPO (35)
2 DIMENSION RCR (35.3) AVS3 (35). AVS^ (35). X (6,4,^,) LL (6), ADP (35.3) 
C02 ENTERS TOTAL NUMBER OF DETERMINATIONS & NUMBER OF CONTROL, KIC, KMV,
C KIV, PPA, & CHC DETERMINATIONS.
3 READ (5,100) M, (LL(I), 1= 1,6)
C03 ENTERS ANGLES OF STATE 3 & 4 TRACINGS, STATE 3 CHART DIVISIONS/ADP
C CYCLE, MICROLITERS 0.0925M ADP/CYCLE & NET CHART DIVISIONS/
C DETERMINATION (MAX OF 3 ADP CYCLES/DETERMINATION)
k READ (5,110) ( (S3(I,J), SMI.J), PO(I, j) , ADP (I , J), J=l,3), CW(I),
C I = 1,M)
5 100 FORMAT (715)



















MILLIGRAMS MLM PROTEIN/DETERMINATION 
PROT =1.91
LOOP CALCULATES & SUMS RATES, ACR & ADP/O FOR EACH CYCLE OF EACH 
DETERMINATION & DETERMINES DIVISORS FOR COMPUTING AVERAGES. 
DO 130 I = 1,M 
INITIALS AVERAGES TO ZERO.
AVS3 (I) = 0.
AVS4 (I) = 0.
ACR(I) = 0.
ADPO(I) = 0.
DO 120 J = 1,3 
CONVERTS DEGREES TO RADIANS.
S3 (I,J) = S3 (I.J)/57.2957795 
Sk (I.J) = S4 (I,J)/57*2957795
COMPUTES TANGENT (SLOPE).
S3 (I,J) = TAN (S3(I,J)> 
(I,J) = TAN (S4(I,J))
COMPUTES OXYGEN CONSUMPTION RATES.
18 S3 (I.J) = (S3 (I.J) *30. *797.V(CW(X) *PROT)
19 S^ (I.J) = (Sk (I,J) *30. *797.V(CW(I) *PR0T)
CIO IF STATEMENTS PROVIDE FOR VARIOUS ADP CYCLES & INCOMPLETE DATA.
20 IF (S3 (I.J). EQ.O.)GO TO Ilk
21 IF (Sk (I,J). EQ.0,)GO TO 115
Cll COMPUTES ACR.
22 RCR (I,J) = S3 (ItJ)/S^ (I.J)
C12 COMPUTES NANOMOLES ADP CONSUMED/CYLCE.
23 ADP (I,J) = ADP (I,J) * 92.5 
C13 COMPUTES ADP/O.
2k PO (I,J) = (ADP (I,J) * CW(I))/PO (I.J) * 797A)
Cl4 SUMS RATES, ACR, ADP/O FOR EACH DETERMINATION.
25 AVS3 (I) = AVS3 (I) + S3 (I,J)
26 AVS14* (I) = AVSif (I) + (I.J)
27 ACR (I) = ACR(I) + RCR (I.j)
28 ADPO (I) = ADPO(I) + PO (I.J)
C15 DEFINES DIVISORS FOR 3 ADP CYCLES.
29 zi = 3.0
30 Z2 = Zl
31 GO TO 120
C16 DEFINES DIVISORS FOR LESS THAN 3 ADP CYCLES.
32 lib Zl = FLOAT (J-l)
33 Z2 = Zl
3k GO TO 125
C17 COMPUTES COMPUTATIONS & DEFINES DIVISORS FOR INCOMPLETE DATA. 
35, 115 AVS3 (I) = AVS3 (I) + S3 (I,J)
36 Zl = FLOAT (J)
37 Z2 = FLOAT (J-l)
38 GO TO 125
39 120 CONTINUE
C18 AVERAGES RATES, ACR, & ADP/O FOR EACH DETERMINATION. 
kO 125 AVS3 (I) = AVS3 (I)/Zl
iR AVSk (I) = AVS1* (I)/Z2
kZ ACR (I) = ACR (I)/Z2
k3 ADPO (I) = ADPO (I)/Z2
kk 130 CONTINUE
45 DO 140 I = 1,6
46 DO 140 j * 1,4
47 DO 140 K = 1,4
C19 INITIALS OUTPUT MATRIX TO ZERO FOR SUMMATIONS PRIOR TO AVERAGING 
C DATA SETS. MATRIX SUBSCRIPTS (I,J,K) ARE DEFINED AS
C I = DATA SET (CONTROL (l), KIC (2), KMV (3), KIV (4), PPA (5), CHC (6))
C J = PARAMETER DESIGNATIONS (STATE 3(1), STATE 4(2), ACR (3),
C ADP/O (4))
C K = PARAMETER DATA ( PARAMETER VALUE (1), AVG DEV (2), STD DEV (3),
C % CON (4))
48 140 X(I,J,K) = 0.
49 N = 0
50 L = 0
C20 OUTER LOOP GROUPS INDIVIDUAL DETERMINATIONS INTO SETS.
51 DO 1000 I = 1,6
C21 IF STATEMENT ACCOUNTS FOR LACK OF CERTAIN DATA SETS.
IF (LL(I). EQ.O.)GO TO 1000 















N = L + 1
C23 REDEFINES FINAL INDEX FOR INNER LOOPS WITH EACH TURN OF OUTER LOOP. 
L = L + LL(I)
C24 LOOP SUMS RATES, ACR, & ADP/O FOR EACH DATA SET 
DO 150 J = N,L
X(I,1,1) = X(I,1,1) + AVS3CJ)
X(I,2,l) = X(I,2,1) + AVS4(J)
X(I,3,1) = X(I,3,1) + ACR(J)
150 X(I,4,l) = X(I,4,1) + ADPO(J)
Z = FLOAT (LL(I))
C25 LOOP AVERAGES EACH PARAMETER VALUE 
DO 160 J - 1,4 
160 X(I,J,1) = X(I,J,1)/Z 
DO 163 J = N,L 
DO 163 K = 1,4
C26 INITIALS USED DATA STORAGE TO ZERO FOR USE AS TEMPORARY STORAGE. 
I63 PO(J,K) = 0
C27 LOOP CALCULATES ABSOLUTE VALUE OF DEVIATION OF MLM PARAMETERS
66 DO 165 J = N,L
6? PO (J.l) =ABS(X(I,1.,1) - AVS3(J))
68 PO (J,2) = ABS(X(I,2,l) - AVS^(J))
69 PO (J,3) = ABS(X(I,3,1) - ACR(J))
70 PO (J.ij-) = ABS(X(Ii^,l) - ADPO(J))
71 DO 165 K = 1,1*
C28 SUMS ABSOLUTE VALUES OF DEVIATIONS.
72 X(I,K,2) = X(I,K,2) + PO(J,K)
C29 SUMS SQUARES OF ABSOLUTE VALUES OF DEVIATIONS.
73 165 X(I,K,3) = X(I,K,3) + P0(J,K)**2.
71* DO 170 J - 1,1*
C30 COMPUTES AVG DEV FOR EACH DATA SET.
75 X(I»J f 2) = X(I,J,2)/Z
C31 COMPUTES STD DEV FOR EACH DATA SET.
76 X(I,J,3) + SQRT(X(I,J,3)/(Z - i;))
C32 COMPUTES % CON FOR EACH DATA SET.
77 170 X(ItJ,Z*) = (X(I, J ,l)/X(l,J ,l)) * 100.
78 1000 CONTINUE
C33 OUTPUT MATRIX PRINTED IN TABULAR FORM WITH COLUMN AND LINE HEADINGS.
C DATA SET POPULATION PRINTED BELOW COLUMN HEADINGS.
79 WRITE (6,200) (LL(I), I = 1,6)
80 200 FORMAT ('O', T15. 'CONTROL', T27, 'KIC', T37, 'KMV', T47, *KIV», T57, 'PPA',
C T67, *CHC'/. ’ ', T9, (6 1 10))
81 WRITE (6,210) ((X(I,1,J), I = 1,6) J = 1,4)
82 WRITE (6,220) ((X(I,2,J), I = 1,6) J = 1,4)
83 WRITE (6,230) ((X(I,3,J), I = 1,6) J = 1,4)
84 WRITE (6,240) ((X(I,4,J), I = 1,6) J = 1,4)
85 210 FORMAT ('O', (T2, 'STATE 3', T13, 6FIO.5/,' ', (T2, 'AVG DEV*, T13,
C 6F10.5)/, ' ', (T2, 'STD DEV*, TI3, 6FIO.5)/,' ', (T2,» % CON', T13,
C 6FIO.5))
86 220 FORMAT ('O', (T2, 'STATE 4*, TI3, 6F10.5)/,' ', (T2, 'AVG DEV*, T13,
C 6F10.5)/, ' (T2, 'STD DEV', T13, 6FIO.5)/, ' ', (T2, » % CON*, T13,
C 6FIO.5))
87 230 FORMAT ('O', (T2, 'ACR ',T13, 6FIO.5)/, ' ', (T2, 'AVG DEV*, T13,




88 240 FORMAT ('O', T2, ADP/O', T13, 6F10.5)/,' (T2, 'AVG DEV', T13





CONTROL KIC KMV KIV PPA CHC
7 2 3 2 4 2
STATE 3 264.84440 277.71700 271.22770 294.33830 242.54510 261.11980
AVG DEV 10.29217 2.97229 6.05827 8.01648 10.25576 18.65442
STD DEV 14.46849 4.20345 7.99991 11.33701 12.99591 26.38132
% CON 100.00000 104.86030 102.41010 III.I362O 91.58022 98.59364
STATE 4 126.15260 151.25580 132.90550 140.99510 151.72610 130.36560
AVG DEV 4.33911 2.71819 2,38438 6.63634 17.37238 11.20471
STD DEV 5.79400 3,84409 3.09853 9.38520 20.10561 15.84585
% CON 100.00000 119.89900 105.35280 III.76540 120.27180 103.33950
\o-o
ACR 2.07484 1.81735 2.04018 2.03424 1.59282 2.02291
AVG DEV 0.14020 0.09975 0.02863 0.09779 0.15052 0.02281
STD DEV 0.17^39 0.14107 0.03921 0.13830 0.18266 0.03226
% CON 100.00000 87.58969 98.32921 98.04314 76.76819 97.49709
ADP/O 1.40956 1.24891 1.38745 1.40528 1.13233 1.43647
AVG DEV 0.16439 0.08597 0.06752 0.13284 0.02449 0.05047
STD DEV 0.20005 0.12157 0.08928 0.18786 0.03620 0.07138
% CON 100.00000 88.60242 98.43095 99.69641 80.33212 101.90900
*To enhance the legibility of the program, extra spaces were added to the program 
statements. In doing so, some COMMENT, DIMENSION, and FORMAT statements 
appear to exceed the ?2 space limitation for punched cards. This extra 
spacing must be taken into account when transcribing the program statements.
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